Table 1.
Clinical and demographic characteristics of renal transplant recipients up to 12 months post-tranplantation (n = 108)
| Parameters | Median (interquatile range) or number (%) |
|---|---|
| Co (ng ml−1) | 6.8 (5.3–10.0) |
| Dose (mg kg−1 day−1) | 0.07 (0.05–0.10) |
| Body weight (kg) | 64.8 (58.5–77.6) |
| Co : dose (ng ml−1 per mg day−1 per kg body weight) | 109.3 (70.3–145.9) |
| Serum creatinine (μmol l−1) | 124.2 (95.5–143.2) |
| Creatinine clearance* (ml min−1 1.73 m−2) | 55.7 (46.8−70.5) |
| Gender (male/female) | 60/48 |
| Receptor's age (years) | 52 (41–58) |
| Donor type (living/deceased) | 18/90 |
| Number of transplant (first/second1) | 95/13 |
| Induction therapy (n, %) | |
| Basiliximab usage | 65 (60.2) |
| ATG usage | 06 (5.6) |
| Duration of the dialysis before Tx (months) | 39 (24–70) |
| CMV infection (n, %) | 24 (22.2) |
| Cold ischaemia (h) | 25 (20–31) |
*
Creatinine clearance was estimated using MDRD equation. Data are expressed as median and interquartile ranges, or absolute numbers and percentiles. ATG, antithymocyte globulin; CMV, cytomegalovirus; Co, Tacrolimus trough concentration; Tx, transplant.